These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26757994)

  • 1. Increased Synthesis of Liver Erythropoietin with CKD.
    de Seigneux S; Lundby AK; Berchtold L; Berg AH; Saudan P; Lundby C
    J Am Soc Nephrol; 2016 Aug; 27(8):2265-9. PubMed ID: 26757994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
    Shinfuku A; Shimazaki T; Fujiwara M; Sato F; Watase H; Numazaki T; Kawakita Y; Mutoh M; Yamasaki H; Takayama N; Kato S; Sugimoto T; Maruyama J
    Am J Nephrol; 2018; 48(3):157-164. PubMed ID: 30176654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
    Landau D; London L; Bandach I; Segev Y
    PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
    Wang W; Zhang MH; Yu Y; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney Mesenchymal Stem Cell-derived Extracellular Vesicles Engineered to Express Erythropoietin Improve Renal Anemia in Mice with Chronic Kidney Disease.
    Choi HY; Kim TY; Lee M; Kim SH; Jhee JH; Lee YK; Kim HJ; Park HC
    Stem Cell Rev Rep; 2022 Mar; 18(3):980-992. PubMed ID: 33651336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.
    Hanudel MR; Eisenga MF; Rappaport M; Chua K; Qiao B; Jung G; Gabayan V; Gales B; Ramos G; de Jong MA; van Zanden JJ; de Borst MH; Bakker SJL; Nemeth E; Salusky IB; Gaillard CAJM; Ganz T
    Nephrol Dial Transplant; 2019 Dec; 34(12):2057-2065. PubMed ID: 30007314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-Regulation of Cardiac Erythropoietin Receptor and its Downstream Activated Signal Transducer Phospho-STAT-5 in a Rat Model of Chronic Kidney Disease.
    Hertzberg-Bigelman E; Barashi R; Levy R; Cohen L; Ben-Shoshan J; Keren G; Entin-Meer M
    Isr Med Assoc J; 2016 Jun; 18(6):326-30. PubMed ID: 27468524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney-synthesized erythropoietin is the main source for the hypoxia-induced increase in plasma erythropoietin in adult humans.
    Lundby AK; Keiser S; Siebenmann C; Schäffer L; Lundby C
    Eur J Appl Physiol; 2014 Jun; 114(6):1107-11. PubMed ID: 24531592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution.
    Aachmann-Andersen NJ; Just Christensen S; Lisbjerg K; Oturai P; Meinild-Lundby AK; Holstein-Rathlou NH; Lundby C; Vidiendal Olsen N
    PLoS One; 2014; 9(10):e110903. PubMed ID: 25335123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red Blood Cell Lifespan Shortening in Patients with Early-Stage Chronic Kidney Disease.
    Li JH; Luo JF; Jiang Y; Ma YJ; Ji YQ; Zhu GL; Zhou C; Chu HW; Zhang HD
    Kidney Blood Press Res; 2019; 44(5):1158-1165. PubMed ID: 31550724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Bronze-da-Rocha E; Rocha-Pereira P; Belo L; Costa E; Santos-Silva A; Reis F
    PLoS One; 2015; 10(4):e0124048. PubMed ID: 25867633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia in kidney transplants without erythropoietic agents: levels of erythropoietin and iron parameters.
    Florit EA; Hadad F; Rodriguez Cubillo B; De la Flor JC; Valga F; Perez Flores I; Calvo Romero N; Valero San Cecilio R; Barrientos Guzman A; Sanchez Fructuoso A
    Transplant Proc; 2012 Nov; 44(9):2590-2. PubMed ID: 23146464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
    Merta M; Sobotová D; Zahálková J; Bitterová Z; Jirka T; Knetl P; Kopenec J; Suchanová J; Vlasák J
    Sb Lek; 2001; 102(1):41-52. PubMed ID: 11830918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum erythropoietin concentrations in patients with anemia--preliminary hemoglobin-related reference ranges.
    Vogeser M; Schiel X
    Clin Lab; 2002; 48(11-12):595-8. PubMed ID: 12465743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice.
    Hitomi H; Kasahara T; Katagiri N; Hoshina A; Mae SI; Kotaka M; Toyohara T; Rahman A; Nakano D; Niwa A; Saito MK; Nakahata T; Nishiyama A; Osafune K
    Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.